Rifampin (injection)

{{DrugProjectFormSinglePage |authorTag=

|genericName=

|aOrAn=

a

|drugClass=

|indication=

|hasBlackBoxWarning=

Yes

|adverseReactions=

|blackBoxWarningTitle= Title

|blackBoxWarningBody= ConditionName:

• Content

|fdaLIADAdult=

Condition1

• Dosing Information

• Dosage

Condition2

• Dosing Information

• Dosage

Condition3

• Dosing Information

• Dosage

Condition4

• Dosing Information

• Dosage

|offLabelAdultGuideSupport=

Condition1

• Developed by:

• Class of Recommendation:

• Strength of Evidence:

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Rifampin (injection) in adult patients.

|offLabelAdultNoGuideSupport=

Condition1

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Rifampin (injection) in adult patients.

|fdaLIADPed=

Condition1

• Dosing Information

• Dosage

Condition2

There is limited information regarding FDA-Labeled Use of Rifampin (injection) in pediatric patients.

|offLabelPedGuideSupport=

Condition1

• Developed by:

• Class of Recommendation:

• Strength of Evidence:

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Rifampin (injection) in pediatric patients.

|offLabelPedNoGuideSupport=

Condition1

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Rifampin (injection) in pediatric patients.

|contraindications=

• Condition1

|warnings=

• Description

Precautions

• Description

|clinicalTrials=

There is limited information regarding Clinical Trial Experience of Rifampin (injection) in the drug label.

|postmarketing=

There is limited information regarding Postmarketing Experience of Rifampin (injection) in the drug label.

|drugInteractions=

• Drug

• Description

|useInPregnancyFDA=

• Pregnancy Category

|useInPregnancyAUS=

• Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Rifampin (injection) in women who are pregnant.

|useInLaborDelivery= There is no FDA guidance on use of Rifampin (injection) during labor and delivery.

|useInNursing= There is no FDA guidance on the use of Rifampin (injection) with respect to nursing mothers.

|useInPed= There is no FDA guidance on the use of Rifampin (injection) with respect to pediatric patients.

|useInGeri= There is no FDA guidance on the use of Rifampin (injection) with respect to geriatric patients.

|useInGender= There is no FDA guidance on the use of Rifampin (injection) with respect to specific gender populations.

|useInRace= There is no FDA guidance on the use of Rifampin (injection) with respect to specific racial populations.

|useInRenalImpair= There is no FDA guidance on the use of Rifampin (injection) in patients with renal impairment.

|useInHepaticImpair= There is no FDA guidance on the use of Rifampin (injection) in patients with hepatic impairment.

|useInReproPotential= There is no FDA guidance on the use of Rifampin (injection) in women of reproductive potentials and males.

|useInImmunocomp= There is no FDA guidance one the use of Rifampin (injection) in patients who are immunocompromised.

|administration=

• Oral

• Intravenous

|monitoring=

There is limited information regarding Monitoring of Rifampin (injection) in the drug label.

• Description

|IVCompat=

There is limited information regarding IV Compatibility of Rifampin (injection) in the drug label.

|overdose=

Acute Overdose

Signs and Symptoms

• Description

Management

• Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Rifampin (injection) in the drug label.

|drugBox=

|mechAction=

|structure=

• Rifampin for injection, USP is a lyophilized powder that contains rifampin 600 mg, sodium formaldehyde sulfoxylate 10 mg, and sodium hydroxide to adjust pH.

• Rifampin is a semisynthetic antibiotic derivative of rifamycin SV. Rifampin is a red-brown crystalline powder very slightly soluble in water at neutral pH, freely soluble in chloroform, soluble in ethyl acetate and in methanol. Its molecular weight is 822.95 and its chemical formula is C43H58N4O12.

• The chemical name for rifampin is either:

3-[[(4-Methyl-1-piperazinyl)imino]methyl]rifamycin

or

5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,20,22–heptamethyl-8-[N-(4-methyl-1- piperazinyl)formimidoyl]-2,7-(epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan-1,11(2H)-dione 21-acetate.

Its structural formula is:

File:Rifampin (injection)01.png

This image is provided by the National Library of Medicine.

|PD=

There is limited information regarding Pharmacodynamics of Rifampin (injection) in the drug label.

|PK=

There is limited information regarding Pharmacokinetics of Rifampin (injection) in the drug label.

|nonClinToxic=

There is limited information regarding Nonclinical Toxicology of Rifampin (injection) in the drug label.

|clinicalStudies=

There is limited information regarding Clinical Studies of Rifampin (injection) in the drug label.

|howSupplied=

|fdaPatientInfo=

There is limited information regarding Patient Counseling Information of Rifampin (injection) in the drug label.

|alcohol=

• Alcohol-Rifampin (injection) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

|brandNames=

• ®

|lookAlike=

• A® — B®

|drugShortage= }}

{{#subobject:

 |Label Page=Rifampin (injection)
 |Label Name=Rifampin (injection)11.png

}}

{{#subobject:

 |Label Page=Rifampin (injection)
 |Label Name=Rifampin (injection)11.png

}}